A Point-of-care Tenofovir Urine Test Improves Accuracy of Self-reported Preexposure Prophylaxis Adherence and Increases Condomless Sex Reporting Among Young Women

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2024 Aug 1

PMID 39088310

Authors

Kidist Zewdie

Timothy Muwonge

Timothy Ssebuliba

Felix Bambia

Olivia Nampewo

Gabrielle Stein

Kenneth K Mugwanya

Katherine K Thomas

Christina Wyatt

Michael T Yin

Guohong Wang

Monica Gandhi

Andrew Mujugira

Renee Heffron

Affiliations

Soon will be listed here.

Abstract

Objectives: We evaluated a recently developed and validated point-of-care urine tenofovir (POC TFV) test to determine whether its use improves the accuracy of self-reported adherence to preexposure prophylaxis (PrEP) and sexual behavior.

Design: We enrolled sexually active HIV-negative women ages 16 to 25 years in Kampala, Uganda.

Methods: Women were followed quarterly for 24 months with HIV prevention counseling, PrEP dispensation, and adherence counseling. Midway through the study, the POC TFV test was introduced as part of routine study procedures. We examined changes in self-reported PrEP adherence, sexual behavior, and accuracy of self-reported PrEP adherence before and after the introduction of the POC TFV test.

Results: A total of 146 women receiving PrEP refills had at least one visit with a POC TFV test administered before the study exit. At baseline, the median age was 19 years [interquartile range (IQR): 18-21] and the majority (76%) reported having condomless sex within the last 3 months. Participants more frequently self-reported low PrEP adherence [odds ratio (OR): 2.96, 95% confidence interval (CI): 1.89-4.67, P = 0.001] and condomless sex (OR: 1.47, 95% CI: 1.04-2.06, P = 0.03) during visits using the test compared with visits without the test. The accuracy of self-reported PrEP adherence (determined by concordance with TFV-diphosphate levels) was greater when the test was used (61 versus 24%, OR: 4.86, 95% CI: 2.85-8.30, P < 0.001).

Conclusion: When the POC TFV test was used, we observed greater reporting of condomless sex, low PrEP adherence, and more accurate reports of PrEP adherence. The test could facilitate honest conversations between clients and providers and warrant further investigation.

References

Castillo-Mancilla J, Haberer J . Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring. Curr HIV/AIDS Rep. 2018; 15(1):49-59. PMC: 5876155. DOI: 10.1007/s11904-018-0377-0. View

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

Celum C, Bukusi E, Bekker L, Delany-Moretlwe S, Kidoguchi L, Omollo V . PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022; 25(7):e25962. PMC: 9278271. DOI: 10.1002/jia2.25962. View

Kinuthia J, Pintye J, Abuna F, Mugwanya K, Lagat H, Onyango D . Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2019; 7(1):e38-e48. PMC: 11498332. DOI: 10.1016/S2352-3018(19)30335-2. View

Mayer K, Molina J, Thompson M, Anderson P, Mounzer K, De Wet J . Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020; 396(10246):239-254. PMC: 9665936. DOI: 10.1016/S0140-6736(20)31065-5. View

Celum C, Delany-Moretlwe S, Baeten J, van der Straten A, Hosek S, Bukusi E . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019; 22 Suppl 4:e25298. PMC: 6643076. DOI: 10.1002/jia2.25298. View

Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye B . PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021; 18(6):e1003670. PMC: 8253429. DOI: 10.1371/journal.pmed.1003670. View

Corneli A, Deese J, Wang M, Taylor D, Ahmed K, Agot K . FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014; 66(3):324-31. PMC: 4059551. DOI: 10.1097/QAI.0000000000000158. View

Hanscom B, Janes H, Guarino P, Huang Y, Brown E, Chen Y . Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. J Acquir Immune Defic Syndr. 2016; 73(5):606-608. PMC: 5175411. DOI: 10.1097/QAI.0000000000001160. View

10.

Haberer J, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J . Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010; 14(6):1340-6. PMC: 2974938. DOI: 10.1007/s10461-010-9799-4. View

11.

Gandhi M, Bacchetti P, Spinelli M, Okochi H, Baeten J, Siriprakaisil O . Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. J Acquir Immune Defic Syndr. 2019; 81(1):72-77. PMC: 6456396. DOI: 10.1097/QAI.0000000000001971. View

12.

Celum C, Gill K, Morton J, Stein G, Myers L, Thomas K . Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020; 23(11):e25636. PMC: 7695999. DOI: 10.1002/jia2.25636. View

13.

Heffron R, Muwonge T, Boyer J, Matovu F, Zia Y, Bagaya M . Bone mineral density, nutrient intake, and physical activity among young women from Uganda. Arch Osteoporos. 2022; 17(1):134. PMC: 11262243. DOI: 10.1007/s11657-022-01155-0. View

14.

Koester K, Liu A, Eden C, Amico K, McMahan V, Goicochea P . Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. AIDS Care. 2015; 27(10):1199-204. PMC: 6107916. DOI: 10.1080/09540121.2015.1039958. View

15.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

16.

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

17.

Hendrix C, Andrade A, Bumpus N, Kashuba A, Marzinke M, Moore A . Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2015; 32(1):32-43. PMC: 4692123. DOI: 10.1089/AID.2015.0182. View

18.

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

19.

Celum C, Delany-Moretlwe S, McConnell M, van Rooyen H, Bekker L, Kurth A . Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc. 2015; 18(4 Suppl 3):20227. PMC: 4509892. DOI: 10.7448/IAS.18.4.20227. View

20.

Corneli A, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F . The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015; 68(5):578-84. DOI: 10.1097/QAI.0000000000000525. View